The inflammasome component Nlrp3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells

Cancer Research

Volumn 70, Issue 24, 2010, Pages 10161-10169

  Van Deventer, Hendrik W ^a   Burgents, Joseph E ^a   Wu, Qing Ping ^b   Woodford, Rita Marie T ^c   Brickey, W June ^a,b   Allen, Irving C ^a   McElvania Tekippe, Erin ^a   Serody, Jonathan S ^a,b   Ting, Jenny P Y ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; DENDRITIC CELL VACCINE; GR 1 ANTIBODY; GRANULOCYTE ANTIBODY; INFLAMMASOME; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; GROWTH INHIBITION; HOST; IMMUNE RESPONSE; IMMUNOGENICITY; LEWIS CARCINOMA; LYMPHOID TISSUE; MELANOMA; MELANOMA CELL; MEMORY T LYMPHOCYTE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SUPPRESSOR CELL; T CELL DEPLETION; T LYMPHOCYTE; TUMOR LOCALIZATION; TUMOR VOLUME; WILD TYPE;

ANIMALS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; DENDRITIC CELLS; INFLAMMASOMES; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MYELOID CELLS; T-LYMPHOCYTES, REGULATORY;

EID: 78650360196     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1921     Document Type: Article

References (51)

1. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27:229-65.
2. Ting J, Lovering R, Alnemri E, et al. The NLR gene family: a standard nomenclature. Immunity 2008;28:285-7.
3. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 2007;7:31-40.
4. Agostini L, Martinon F, Burns K, McDermott M.F, Hawkins P, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-25.
5. Kono H, Rock K. How dying cells alert the immune system to danger. Nat Rev Imm 2008;8:279-89.
6. Guo L, Wei G, Shu J, et al. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci U S A 2009;106:13463-8.
7. Shi Y, Zheng W, Rock K. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci U S A 2000;97:14590-5.
8. Schroder K, Zhou R, Tschopp J. The NLRP3 Inflammasome: a sensor for metabolic danger? Science 2010;327:296-300.
9. Saijo Y, Tanaka M, Miki M, et al. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol 2002;169:469-75.
10. Krelin Y, Voronov E, Dotan S, et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 2007;67:1062-71.
11. Lavi G, Voronov E, Dinarello CA, Apte RN, Cohen S. Sustained delivery of IL-1Rα from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases. J Control Release 2007;123:123-30.
12. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 2003;100:2645-50.
13. El-Omar EM, Carrington M, Chow WH, McColl KL, Bream JH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
14. Nikiteas N, Yannopoulos A, Chatzitheofylaktou A, Tsigris C. Heterozygosity for interleukin-18 607 A/C polymorphism is associated with risk for colorectal cancer. Anticancer Res 2007;27:3849-53.
15. Tangkijvanich P, Thong-Ngam D, Mahachai V, Theamboonlers A, Poovorawan Y. Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol 2007;13:4345-9.
16. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1β induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008;14:408-19.
17. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010;185: 2273-84.
18. Gabrilovich D, Bronte V, Chen S, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007;67:425-6.
19. Talmadge J. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007;13:5243-8.
20. Huang B, Pan P, Li Q, et al. Gr-1+CD115 + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006;66:1123-31.
21. Sinha P, Clements V, Bunt S, Albelda S, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007;179:977-83.
22. Hoechst B, Voigtnaender T, Ormandy L, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009;50:799-807.
23. Yang L, DeBusk LM, Fukuda K, et al. Expansion of myeloid immune suppressor Gr+CD11b + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-21.
24. Diaz-Montero C, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009;58:49-59.
25. Young M, Lathers D. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int Immunopharmacol 1999;21:241-52.
26. Zea A, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044-8.
27. Melani C, Chiodoni C, Forni G, Colombo M. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003;102:2138-45.
28. Willingham SB, Allen IC, Bergstralh DT, et al. NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and-independent pathways. J Immunol 2009;183:2008-15.
29. Moran T, Burgents JE, Long B, et al. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-over-expressing tumors in wild-type mice. Vaccine 2007;25:6604-12.
30. van Deventer H, Wu QP, Bergstralh DT, et al. C-C chemokine receptor 5 on pulmonary fibrocytes facilitates migration and promotes metastasis via matrix metalloproteinase 9. Am J Pathol 2008;173:253-64.
31. Burgents JE, Moran TP, West ML, Davis NL, Johnston RE, Serody JS. The immunosuppressive tumor environment is the major impediment to successful therapeutic vaccination in Neu transgenic mice. J Immunother 2010;33:482-91.
32. Youn J-I, Nagaraj S, Collazo M, Gabrilovich D. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008;181:5791-802.
33. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363: 411-22.
34. Ko JS, Rayman P, Ireland J, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010;70:3526-36.
35. Li H, Ambade A, Re F. Cutting Edge: necrosis activates the NLRP3 inflammasome. J Immunol 2009;183:1528-32.
36. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009;10:1170-8.
37. Iyer S, Pulskens WP, Sadler JJ, et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A 2009;106:20388-93.
38. Stoppacciaro A, Melani C, Parenza M, et al. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cellproduced interferon gamma. J Exp Med 1993;178:151-61.
39. Terabe M, Matsui S, Park JM, et al. Transforming growth factor-{beta} production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003;198:1741-52.
40. Nausch N, Galani IE, Schlecker E, Cerwenka A. Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood 2008;112:4080-9.
41. Matsuzaki J, Tsuji T, Chamoto K, Takeshima T, Sendo F, Nishimura T. Successful elimination of memory-type CD8+ T cell subsets by the administration of anti-Gr-1 monoclonal antibody in vivo. Cell Immunol 2003;224:98-105.
42. Seung LP, Rowley DA, Dubey P, Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci U S A 1995;92:6254-8.
43. Dolcetti L, Peranzoni E, Ugel S, et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2009;40:22-35.
44. Kool M, Petrilli V, DeSmedt T, et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through the activation of the NALP3 inflammasome. J Immunol 2008;181:3755-9.
45. Bjorkdahl O, Wingren A, Hedhund G, Ohlsson L, Dohlsten M. Vaccination with B16 melanoma cells expressing a secreted form of interleukin- 1β induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor. Cancer Immunol Immunother 1997;44:273-81.
46. Bunt S, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007;67:10019-26.
47. Fujisawa A, Kambe N, Saito M, et al. Disease-associated mutations in CIAS1 induce cathepsin B-dependent rapid cell death of human THP-1 monocytic cells. Blood 2007;109:2903-11.
48. Liu C, Yu S, Kappes J, et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 2007;109:4336-42.
49. Ilkovitch D, Lopez D. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res 2009;69:5514-21.
50. Kochenderfer JN, Gress RE. A comparison and critical analysis of preclinical anticancer vaccination strategies. Exp Biol Med (Maywood) 2007;232:1130-41.
51. Hornung V, Ablasser A, Charrel-Dennis M, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009;458:514-8.